Otwarty dostęp

Protective Effects of Quercetin, Curcumin and Resveratrol in an in Vitro Model of Doxorubicin-Induced Cardiotoxicity

, ,  oraz   
09 wrz 2025

Zacytuj
Pobierz okładkę

Introduction

Over the past two decades, drug-induced cardiotoxicity has resulted in the withdrawal of several drugs, including prenylamine, rofecoxib, and levomethadyl acetate, while others like rosiglitazone remain available only under restricted conditions. However, some cardiotoxic drugs, like doxorubicin (DOX), are still used due to their potent antitumor activity despite their dose-dependent cardiotoxicity. This cardiotoxicity, often caused by lipid peroxidation and reactive oxygen species (ROS), can be mitigated by natural substances like quercetin (QR), curcumin (CRC), and resveratrol (RES), which have notable antioxidant and cardioprotective effects.

Aim

This study aimed to evaluate the potential of QR, RES, and CRC to enhance the viability of H9c2 cardiomyocytes in an in vitro model of doxorubicin-induced cardiotoxicity.

Materials and Methods

H9c2 cells were treated with doxorubicin (0.25 μM and 1 μM) and varying concentrations of QR, RES, and CRC (0.01 μM, 0.1 μM, 1 μM, 2.5 μM, 5 μM, 10 μM) for 24 and 48 h. Cell viability was assessed using the MTT assay to determine the protective effects of the natural antioxidants on H9c2 cell line.

Results

Our data demonstrated that QR and CRC significantly improved the viability of H9c2 cells in the DOX-induced cardiotoxicity model of treatment with 0.25 μM DOX (24 h). At these conditions, RES also showed protective cell viability effects, but it was not effective at the injury with higher DOX concentration (1 μM, 24 h).

Conclusions

This study highlights the in vitro protective effects of QR and CRC in reducing DOX-induced cardiotoxicity in H9c2 cardioblast cells, most probably attributed to their well-established antioxidant effects.

Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Medycyna, Podstawowe nauki medyczne, Immunologia, Medycyna kliniczna, Medycyna kliniczna, inne